Correlation between CA125 level dynamics, immune characteristics and prognosis in recurrent ovarian cancer patients receiving bevacizumab combined with paclitaxel and carboplatin chemotherapy

KONG Xiaoxia, XIE Yutao, ZHOU Li, HU Luyu

PDF(2434 KB)
Tumor website：www.tumorsci.org E-mail Alert
PDF(2434 KB)
Tumor ›› 2026, Vol. 46 ›› Issue (03) : 201-216. DOI: 10.3781/j.issn.1000-7431.2026.2510-0725
Original Research

Correlation between CA125 level dynamics, immune characteristics and prognosis in recurrent ovarian cancer patients receiving bevacizumab combined with paclitaxel and carboplatin chemotherapy

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2026, 46(03): 201-216 https://doi.org/10.3781/j.issn.1000-7431.2026.2510-0725

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(2434 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Tumor, All Rights Reserved.
E-mail: tumor@tumorsci.org
Powered by Beijing Magtech Co., Ltd.

/

〈 〉